Ara-290vsVIP

Ara-290 is an 11-amino-acid peptide designed to selectively activate the innate repair receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131/βcR). This receptor is distinct from the classical homodimeric EPOR that mediates erythropoiesis, which is why Ara-290 can deliver tissue-protective effects without stimulating red blood cell production or the thrombotic risks associated with EPO.

The IRR is expressed on tissues subjected to metabolic stress, inflammation, or injury — including neurons, Schwann cells, cardiomyocytes, renal tubular cells, and endothelial cells. When Ara-290 activates the IRR, it triggers a cascade of protective signaling pathways: JAK2/STAT5 activation promotes anti-apoptotic gene expression (Bcl-2, Bcl-xL); PI3K/Akt signaling provides cell survival signals; NF-κB modulation shifts the inflammatory balance from pro-inflammatory to pro-resolution. The net effect is protection of viable cells from death, reduction of inflammation, and activation of repair processes.

Ara-290's most clinically advanced application is in peripheral neuropathy, particularly diabetic small fiber neuropathy. Schwann cells — the myelinating glial cells of the peripheral nervous system — express the IRR, and Ara-290 stimulates their survival and regenerative capacity. In clinical trials, subcutaneous Ara-290 administration improved corneal nerve fiber density (a measure of small fiber regeneration) and reduced neuropathic symptoms. Despite its extremely short plasma half-life (approximately 2 minutes), the tissue-protective effects persist for days because the cellular signaling cascades activated by IRR engagement have sustained downstream effects that outlast the peptide's presence in circulation.

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily. It is widely distributed throughout the body — found in neurons of the central and peripheral nervous systems, immune cells, and the gastrointestinal tract — and acts through two G protein-coupled receptors: VPAC1 (expressed broadly) and VPAC2 (more restricted to CNS and immune tissue). Both receptors couple to Gs proteins, activating adenylyl cyclase and raising intracellular cAMP.

VIP's vasodilatory effect is among the most potent in the body. It relaxes vascular, airway, and gastrointestinal smooth muscle by activating cAMP/PKA signaling, which phosphorylates myosin light chain kinase and reduces calcium sensitivity in smooth muscle cells. In the pulmonary vasculature, this produces bronchodilation and reduced pulmonary artery pressure. In cerebral vasculature, VIP is a key regulator of blood flow.

The immunomodulatory effects are particularly relevant for its use in chronic inflammatory response syndrome (CIRS). VIP powerfully suppresses the Th1 (pro-inflammatory) immune response while promoting Th2 and regulatory T cell (Treg) differentiation. It inhibits macrophage production of TNF-α, IL-6, IL-12, and nitric oxide, and suppresses dendritic cell maturation and antigen presentation. This immune-balancing effect makes VIP valuable in conditions characterized by chronic Th1/Th17 immune dysregulation, such as mold illness/CIRS. In the brain, VIP is neuroprotective — it upregulates BDNF and activity-dependent neuroprotective protein (ADNP), supports circadian rhythm regulation in the suprachiasmatic nucleus, and protects neurons from inflammatory and oxidative damage. The extremely short plasma half-life (1-2 minutes) necessitates intranasal delivery for CNS effects, bypassing the blood-brain barrier through olfactory and trigeminal nerve transport.